Report cover image

Europe Monoclonal Antibodies In Veterinary Health Market Size, Share & Industry Analysis Report By Animal Type (Dogs and Other Animal Type), By Scope (Dermatology, Pain, and Other Scope), By End User (Veterinary Hospitals and Other End User), By Country a

Publisher Knowledge Based Value (KBV) Research
Published Jun 30, 2025
Length 148 Pages
SKU # KBV20173067

Description

The Europe Monoclonal Antibodies In Veterinary Health Market would witness market growth of 18.3% CAGR during the forecast period (2025-2032).

The Germany market dominated the Europe Monoclonal Antibodies In Veterinary Health Market by Country in 2024, and would continue to be a dominant market till 2032; thereby, achieving a market value of $216.2 million by 2032. The UK market is exhibiting a CAGR of 16.9% during (2025 - 2032). Additionally, The France market would experience a CAGR of 19.1% during (2025 - 2032).

The European veterinary healthcare landscape has undergone a significant transformation over the past decade, with monoclonal antibodies (mAbs) emerging as a pivotal innovation in animal therapeutics. Initially developed for human medicine, mAbs are laboratory-engineered molecules designed to target specific antigens. Their precision and efficacy have now been successfully adapted to veterinary medicine, marking a turning point in the treatment of chronic and complex animal diseases.

The journey of monoclonal antibodies in European veterinary health began as part of a broader shift toward biologics, which are biotechnological products derived from living organisms. Their introduction was driven by the growing demand for targeted, safe, and long-lasting treatments for conditions such as allergic dermatitis, osteoarthritis, and chronic inflammation in companion animals. Traditional pharmaceuticals, often limited by systemic side effects or short efficacy windows, created a gap that mAbs have started to fill effectively.

Germany represents one of the most advanced veterinary markets in Europe, underpinned by high pet ownership, strong veterinary infrastructure, and substantial investment in animal healthcare. As a leader in both agricultural production and companion animal welfare, Germany is positioned well for rapid adoption of monoclonal antibodies (mAbs) in veterinary use. German veterinarians and pet owners increasingly seek precision-targeted treatments—especially for chronic conditions such as osteoarthritis, atopic dermatitis, and certain cancers. The nation’s robust biotech sector, known for its human biologics expertise, is now pivoting toward veterinary applications.

The UK veterinary market for mAbs is among the most progressive in Europe, shaped by high companion animal ownership and a cultural tendency to treat pets akin to family. The strong human biologics sector in the UK—including established antibody platforms—offers a significant competitive advantage when transitioning to veterinary applications. Regulatory structures, such as the VMD underpinned by EMA guidance, ensure high safety and efficacy standards, boosting stakeholder confidence in novel treatments.

France’s veterinary mAb market benefits from high per capita pet ownership and strong animal welfare traditions. The French veterinary system blends public accountability with private clinic capacities, which are well poised to adopt biologics. Veterinary schools—such as those in Lyon and Toulouse—have begun pilot research into anti NGF therapeutics and monoclonal diagnostics for infectious diseases. In conclusion, Europe's structured regulatory support and early adoption of biologics have positioned it as a mature and steadily growing market for veterinary monoclonal antibodies.

Based on Animal Type, the market is segmented into Dogs and Other Animal Type. Based on Scope, the market is segmented into Dermatology, Pain, and Other Scope. Based on End User, the market is segmented into Veterinary Hospitals and Other End User. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

List of Key Companies Profiled
  • Zoetis, Inc.
  • Virbac
  • Merck KGaA
  • Elanco Animal Health, Inc.
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale
  • Phibro Animal Health Corporation
  • Indian Immunologicals Ltd.
Europe Monoclonal Antibodies In Veterinary Health Market Report Segmentation

By Animal Type
  • Dogs
  • Other Animal Type
By Scope
  • Dermatology
  • Pain
  • Other Scope
By End User
  • Veterinary Hospitals
  • Other End User
By Country
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe

Table of Contents

148 Pages
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Monoclonal Antibodies In Veterinary Health Market, by Animal Type
1.4.2 Europe Monoclonal Antibodies In Veterinary Health Market, by Scope
1.4.3 Europe Monoclonal Antibodies In Veterinary Health Market, by End User
1.4.4 Europe Monoclonal Antibodies In Veterinary Health Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.2.3 Market Opportunities
3.2.4 Market Challenges
3.3 Porter Five Forces Analysis
Chapter 4. Value Chain Analysis of Monoclonal Antibodies In Veterinary Health Market
4.1 Research & Development (R&D)
4.2 Regulatory & Clinical Trials
4.3 Technology Transfer & Process Validation
4.4 Manufacturing
4.5 Packaging & Distribution
4.6 Marketing & Veterinary Engagement
4.7 Post-Market Surveillance & Pharmacovigilance
4.8 Customer Feedback & Support
Chapter 5. Key Costumer Criteria - Monoclonal Antibodies In Veterinary Health Market
Chapter 6. Europe Monoclonal Antibodies In Veterinary Health Market by Animal Type
6.1 Europe Dogs Market by Country
6.2 Europe Other Animal Type Market by Country
Chapter 7. Europe Monoclonal Antibodies In Veterinary Health Market by Scope
7.1 Europe Dermatology Market by Country
7.2 Europe Pain Market by Country
7.3 Europe Other Scope Market by Country
Chapter 8. Europe Monoclonal Antibodies In Veterinary Health Market by End User
8.1 Europe Veterinary Hospitals Market by Country
8.2 Europe Other End User Market by Country
Chapter 9. Europe Monoclonal Antibodies In Veterinary Health Market by Country
9.1 Germany Monoclonal Antibodies In Veterinary Health Market
9.1.1 Germany Monoclonal Antibodies In Veterinary Health Market by Animal Type
9.1.2 Germany Monoclonal Antibodies In Veterinary Health Market by Scope
9.1.3 Germany Monoclonal Antibodies In Veterinary Health Market by End User
9.2 UK Monoclonal Antibodies In Veterinary Health Market
9.2.1 UK Monoclonal Antibodies In Veterinary Health Market by Animal Type
9.2.2 UK Monoclonal Antibodies In Veterinary Health Market by Scope
9.2.3 UK Monoclonal Antibodies In Veterinary Health Market by End User
9.3 France Monoclonal Antibodies In Veterinary Health Market
9.3.1 France Monoclonal Antibodies In Veterinary Health Market by Animal Type
9.3.2 France Monoclonal Antibodies In Veterinary Health Market by Scope
9.3.3 France Monoclonal Antibodies In Veterinary Health Market by End User
9.4 Russia Monoclonal Antibodies In Veterinary Health Market
9.4.1 Russia Monoclonal Antibodies In Veterinary Health Market by Animal Type
9.4.2 Russia Monoclonal Antibodies In Veterinary Health Market by Scope
9.4.3 Russia Monoclonal Antibodies In Veterinary Health Market by End User
9.5 Spain Monoclonal Antibodies In Veterinary Health Market
9.5.1 Spain Monoclonal Antibodies In Veterinary Health Market by Animal Type
9.5.2 Spain Monoclonal Antibodies In Veterinary Health Market by Scope
9.5.3 Spain Monoclonal Antibodies In Veterinary Health Market by End User
9.6 Italy Monoclonal Antibodies In Veterinary Health Market
9.6.1 Italy Monoclonal Antibodies In Veterinary Health Market by Animal Type
9.6.2 Italy Monoclonal Antibodies In Veterinary Health Market by Scope
9.6.3 Italy Monoclonal Antibodies In Veterinary Health Market by End User
9.7 Rest of Europe Monoclonal Antibodies In Veterinary Health Market
9.7.1 Rest of Europe Monoclonal Antibodies In Veterinary Health Market by Animal Type
9.7.2 Rest of Europe Monoclonal Antibodies In Veterinary Health Market by Scope
9.7.3 Rest of Europe Monoclonal Antibodies In Veterinary Health Market by End User
Chapter 10. Company Profiles
10.1 Zoetis, Inc.
10.1.1 Company Overview
10.1.2 Financial Analysis
10.1.3 Regional Analysis
10.1.4 Research & Development Expenses
10.1.5 Recent strategies and developments:
10.1.5.1 Product Launches and Product Expansions:
10.1.6 SWOT Analysis
10.2 Virbac
10.2.1 Company Overview
10.2.2 Financial Analysis
10.2.3 Regional Analysis
10.2.4 Recent strategies and developments:
10.2.4.1 Partnerships, Collaborations, and Agreements:
10.2.5 SWOT Analysis
10.3 Merck KGaA
10.3.1 Company Overview
10.3.2 Financial Analysis
10.3.3 Segmental and Regional Analysis
10.3.4 Research & Development Expenses
10.3.5 SWOT Analysis
10.4 Elanco Animal Health, Inc.
10.4.1 Company Overview
10.4.2 Financial Analysis
10.4.3 Regional Analysis
10.4.4 Research & Development Expenses
10.4.5 SWOT Analysis
10.5 Boehringer Ingelheim International GmbH
10.5.1 Company Overview
10.5.2 Financial Analysis
10.5.3 Segmental and Regional Analysis
10.5.4 Research & Development Expenses
10.5.5 SWOT Analysis
10.6 Ceva Sante Animale
10.6.1 Company Overview
10.6.2 SWOT Analysis
10.7 Phibro Animal Health Corporation
10.7.1 Company Overview
10.7.2 Financial Analysis
10.7.3 Segmental and Regional Analysis
10.7.4 Research & Development Expenses
10.8 Indian Immunologicals Ltd.
10.8.1 Company Overview

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us